Gilead Sciences (GILD) Non-Current Debt (2010 - 2026)
Gilead Sciences' (GILD) quarterly Non-Current Debt came in at $20.9 billion in Q1 2026, down 16.4% YoY from $25.0 billion in Q1 2025, and down 5.73% on a QoQ basis from $22.1 billion in Q4 2025.
Gilead Sciences (GILD) Non-Current Debt (2010 - 2026) Analysis & Trends
Gilead Sciences (GILD) has 17 years of Non-Current Debt data on file, last reported at $20.9 billion in Q1 2026.
- Quarterly Non-Current Debt fell 16.4% year-over-year to $20.9 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $20.9 billion (down 16.4% YoY) and the FY2025 annual result came in at $22.1 billion, down 11.11% from the prior year.
- Non-Current Debt fell to $20.9 billion in Q1 2026, from $22.1 billion in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $26.2 billion in Q2 2022 to a low of $20.9 billion in Q1 2026.
- A 5-year average of $23.7 billion and a median of $23.3 billion in 2024 frame the typical range for Non-Current Debt.
- Annual changes were most pronounced in 2022 — Non-Current Debt slipped 17.1% — and 2025, when it gained 15.91%.
- Tracing GILD's Non-Current Debt over 5 years: stood at $23.0 billion in 2022, then increased by 8.84% to $25.0 billion in 2023, then decreased by 0.36% to $24.9 billion in 2024, then decreased by 11.11% to $22.1 billion in 2025, then retreated by 5.73% to $20.9 billion in 2026.
- The last three Non-Current Debt figures came in at $20.9 billion (Q1 2026), $22.1 billion (Q4 2025), and $22.1 billion (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 37.34 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 62.48 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 51.08 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 23.68 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 57.30 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 26.25 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 60.50 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | -18.71 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | 17.02 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 26.25 Bn |
| Mar 31, 2026 | 20.86 Bn |
| Dec 31, 2025 | 22.13 Bn |
| Sep 30, 2025 | 22.14 Bn |
| Jun 30, 2025 | 24.95 Bn |
| Mar 31, 2025 | 24.95 Bn |
| Dec 31, 2024 | 24.90 Bn |
| Sep 30, 2024 | 23.25 Bn |
| Jun 30, 2024 | 23.35 Bn |
| Mar 31, 2024 | 21.53 Bn |
| Dec 31, 2023 | 24.99 Bn |
| Sep 30, 2023 | 24.98 Bn |
| Jun 30, 2023 | 25.25 Bn |
| Mar 31, 2023 | 22.96 Bn |
| Dec 31, 2022 | 22.96 Bn |
| Sep 30, 2022 | 22.95 Bn |
| Jun 30, 2022 | 26.22 Bn |
| Mar 31, 2022 | 25.18 Bn |
| Dec 31, 2021 | 26.70 Bn |
| Sep 30, 2021 | 27.69 Bn |